Ardena Signs Agreement to Expand US Footprint with the Acquisition of Advanced Drug Product Manufacturing Facility from Catalent

Group 1 - Ardena has signed a definitive agreement to acquire Catalent's facility in Somerset, New Jersey, enhancing its capabilities in downstream late-stage and small-scale commercial manufacturing of oral drug products [1][2] - The Somerset facility is FDA-approved and employs approximately 200 skilled scientists and technicians, serving as a Center of Excellence for advanced delivery of oral dosage forms [2][3] - This acquisition will allow Ardena to expand its bioanalytical services in the US, addressing the growing demand for advanced drug development services [2][3] Group 2 - The CEO of Ardena, Jeremie Trochu, emphasized that this acquisition marks a significant milestone in the company's international growth strategy and aligns with its core values [3] - The addition of advanced technologies such as Hot Melt Extrusion will enhance Ardena's bioavailability improvement solutions and align with its expertise in innovative nanomedicine drug delivery systems [3] - GHO Capital, Ardena's private equity partner, has played a crucial role in facilitating this acquisition, which is expected to close in early 2025, pending regulatory approvals [3]